-
Sector Analysis
NewDiabetic Nephropathy (DN) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Diabetic Nephropathy (DN) Marketed and Pipeline Drugs Report Overview Diabetic Nephropathy (DN) is glomerular sclerosis and fibrosis caused by the metabolic and hemodynamic changes of diabetes mellitus (DM). It manifests as slowly progressive albuminuria with worsening hypertension and renal insufficiency. DN is the most common cause of nephrotic syndrome in adults and is also the most common cause of end-stage renal disease (ESRD) in the US, accounting for up to 80% of cases. Renal failure is particularly common in certain...
-
Product Insights
NewAmyloidosis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Amyloidosis Clinical Trials Market Report Overview The Amyloidosis clinical trial market research report provides an overview of the Amyloidosis clinical trials scenario. This report provides top-line data relating to the clinical trials on Amyloidosis and includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report also offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type. It provides prominent drugs...
-
Sector Analysis
Dyslipidemia in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2032
Dyslipidemia Market Report Overview The Dyslipidemia market size across the 7MM was valued at $5.56 billion in 2022 and is expected to achieve a CAGR of more than 10% during 2022-2032. In 2022, the US made up the majority of total global sales. The 7MM includes the US, 5EU (France, Germany, Italy, Spain, and the UK), and Japan Dyslipidemia Market Outlook, 2022-2032 ($ Billion) Buy Full Report to Know More about The Dyslipidemia Market Forecast | Download A Free Report...
-
Thematic Analysis
Digital Marketing Trends in Type 2 Diabetes
Digital Marketing Trends in Type 2 Diabetes Report Overview Novo Nordisk's Ozempic.com achieved the highest total traffic across type 2 diabetes (T2D) patient brand sites in the US, with over 23 million visitors between April 2022–March 2023, followed by Eli Lilly's Trulicity.com and AstraZeneca's Farxiga.com. The highest proportion of traffic to branded patient T2D websites originated from direct sources, followed by organic. Novo Nordisk’s Rybelsus.com had the highest proportion of direct traffic. The Digital Marketing Trends in the Type 2...
-
Sector Analysis
Dyslipidemia Epidemiology Analysis and Forecast to 2032
Dyslipidemia Market Report Overview In the 7MM, there were 287,608,383 diagnosed prevalent cases of Dyslipidemia in 2022. The cases are expected to achieve an AGR of less than 1% during the period 2022-2032Of the 7MM, the US is expected to have the highest number of total prevalent cases, and Italy will have the lowest number of total prevalent cases of dyslipidemia in 2032. Dyslipidemia Market Outlook, 2022-2032 (Diagnosed Prevalent Cases) For more insights into the Dyslipidemia market forecast, download a...
-
Product Insights
Diabetic Macular Edema Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Diabetic Macular Edema Clinical Trials Market Report Overview The Diabetic Macular Edema Clinical Trials market research report provides an overview of Diabetic Macular Edema Clinical trials scenario. This report provides top line data relating to the clinical trials on Diabetic Macular Edema. The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points...
-
Product Insights
Hyperglycemia Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Hyperglycemia Clinical Trials Market Report Overview The hyperglycemia clinical trial market research report provides an overview of hyperglycemia clinical trials scenario. This report provides top line data relating to the clinical trials on Hyperglycemia. The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. The report also provides...
-
Sector Analysis
Obesity Market Size, Drug Analysis, Epidemiology, Disease Management, Pipeline Assessment, Unmet Needs and Forecast to 2031
Obesity Market Report Overview The obesity market size across the 7MM was valued at $2.43 billion in 2021 and is expected to achieve a CAGR of more than 31% during 2021-2031. The US is anticipated to account for more than 74% of the global market which is mainly attributable to its large population, higher drug prices, and consistently high treatment rates. However, the country is likely to experience the slowest growth during the forecast period. Obesity Market Outlook, 2021-2031 ($...
-
Product Insights
Hypoglycemia Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Hypoglycemia Clinical Trials Market Report Overview The Hypoglycemia clinical trial market research report provides an overview of the Hypoglycemia clinical trials scenario. The report provides top-line data relating to the clinical trials on Hypoglycemia. It also includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type.
-
Sector Analysis
Painful Diabetic Neuropathy Epidemiology Analysis and Forecast to 2031
Painful Diabetic Neuropathy Market Report Overview The total prevalent cases of Painful Diabetic Neuropathy (PDN) were 7,472,695 cases in the seven major markets (7MM) in 2021 and are expected to achieve an AGR of more than 1% during 2021-2031. Diabetic neuropathy refers to a variety of syndromes that differ in clinical course, distribution, and fiber involvement. Symptoms of diabetic neuropathy vary widely from patient to patient, and some patients with diabetic neuropathy have no symptoms. The PDN market research report...
-
Sector Analysis
Overweight and Obesity Epidemiology Analysis and Forecast to 2031
Overweight and Obesity Epidemiology Analysis Report Overview The combined diagnosed prevalent cases of overweight and obesity were 276,919,516 in the seven major markets (7MM) in 2021. Changes in the total and diagnosed prevalent cases of overweight and obesity throughout the forecast can be attributed to both increasing disease prevalence and the population dynamics in each market. Some heritable traits predispose individuals to obesity, but most factors leading to its onset are behavioral. The widening prevalence of unhealthy diets and sedentary...
-
Sector Analysis
Type 2 Diabetes Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2019-2029
Type 2 Diabetes (T2D) Market Report Overview The T2D market value for the 9 markets (9MM) was $45.9 billion in 2019. T2D is a chronic disease characterized by insulin resistance and pancreatic β-cell failure, as defined by the International Classification of Diseases 11th edition (ICD-11), with an underlying genetic predisposition heavily influenced by diet and lifestyle. This disease is a multi-causal, heterogeneous, and progressive cardiometabolic condition that is commonly associated with obesity, dyslipidemia, hypertension, inflammation, and endothelial dysfunction. The prevalence...
-
Product Insights
Familial Amyloid Neuropathies Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Familial Amyloid Neuropathies Pipeline Drugs Market Report Overview Familial amyloid neuropathy is a slowly progressive condition characterized by the buildup of abnormal deposits of a protein called amyloid (amyloidosis) in the body's organs and tissues. Symptoms include numbness, tingling, pins, and needles in the feet and hands, weakness and pain in the arms and legs, loss of sensation, urinary retention, reduced sweating, ankle swelling, fatigue, nausea, weight loss, dizziness, and fainting. The Familial Amyloid Neuropathies pipeline drugs market research report...
-
Product Insights
Hyperglycemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Hyperglycemia Pipeline Drugs Development Market Report Overview Hyperglycemia is a condition that occurs when blood glucose levels get too high. Several factors can contribute to hyperglycemia, including food and physical activity choices, illness, non-diabetes medications, or not taking enough glucose-lowering medication. Symptoms include frequent urination, blurred vision, fatigue headache, nausea and vomiting, dry mouth, coma and confusion. Treatment includes anti-hyperglycemic therapy and insulin therapy. The Hyperglycemia pipeline drugs market research report provides comprehensive information on the therapeutics under development for...
-
Product Insights
Hyperinsulinemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Hyperinsulinemia Drugs Development Market Report Overview Hyperinsulinemia is a condition in which there are excess levels of insulin circulating in the blood relative to the level of glucose. Insulin resistance is the primary cause of hyperinsulinemia. Symptoms include weight gain, anxiety, fatigue, and frequent hunger. The Hyperinsulinemia pipeline market research report provides comprehensive information on the therapeutics under development for Hyperinsulinemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule...
-
Product Insights
Pituitary ACTH Hypersecretion (Cushing Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Pituitary ACTH Hypersecretion Pipeline Drugs Market Report Overview Cushing’s disease is a condition that results from hypersecretion of adrenocorticotropic hormone (ACTH) due to a pituitary gland tumor. Symptoms include acne or skin infections, backache, mental changes (such as depression, anxiety, or changes in behavior), menstrual disorders, and weight gain. Treatment includes radiation, chemotherapy, and the use of certain hormone-inhibiting drugs. The pituitary ACTH hypersecretion pipeline products market research report provides comprehensive information on the therapeutics under development for pituitary ACTH...
-
Sector Analysis
Diabetic Foot Ulcers Treatment Market Size, Share and Trends Analysis by Region, Treatment (Biologics, Wound Care Dressings, Therapy Devices, and Others), Ulcers Type (Neuro-ischemic Ulcers, Neuropathic Ulcers, and Ischemic Ulcers), End-user (Homecare Settings, Hospitals and Specialty Clinics, Others) and Segment Forecast, 2022-2027
The diabetic foot ulcers market size was valued at US$ 4.74 billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 7.1% during 2022-2027. The key to the growth has been the rising prevalence of diabetes and resulting increase in incidence of diabetic foot ulcers. Additionally, rise in geriatric population, and increasing adoption of novel biologics and wound care devices for treatment, favoring diabetic foot ulcers market growth.
-
Product Insights
Diabetic Retinopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Diabetic Retinopathy Drugs Market Report Overview Diabetic retinopathy is a complication of diabetes that affects the eyes. The symptoms may include spots or dark strings floating in vision (floaters), blurred vision, fluctuating vision, vision loss, and difficulty with color perception. The Diabetic Retinopathy pipeline drugs market research report provides comprehensive information on the therapeutics under development for Diabetic Retinopathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule...
-
Product Insights
Type 1 Diabetes (Juvenile Diabetes) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Type 1 Diabetes Pipeline Drugs Market Report Overview Type 1 diabetes (T1D) occurs when the body’s immune system attacks and destroys the insulin-producing cells in the pancreas. The signs and symptoms of type 1 diabetes include increased thirst and frequent urination, extreme hunger, weight loss, fatigue, and irritability or unusual behavior. The Type 1 Diabetes pipeline drugs market research report provides comprehensive information on the therapeutics under development for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders), complete with analysis by...
-
Product Insights
Obesity Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Obesity is defined as having an excessive amount of body fat. Obesity increases the risk of diseases and health problems such as heart disease, diabetes, and high blood pressure. The predisposing factors include age, family history, smoking, lack of sleep, and certain medications. The obesity pipeline drugs market research report provides comprehensive information on the therapeutics under development for obesity, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type....
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.